801 related articles for article (PubMed ID: 9223550)
1. S 15535, a novel benzodioxopiperazine ligand of serotonin (5-HT)1A receptors: II. Modulation of hippocampal serotonin release in relation to potential anxiolytic properties.
Millan MJ; Hjorth S; Samanin R; Schreiber R; Jaffard R; De Ladonchamps B; Veiga S; Goument B; Peglion JL; Spedding M; Brocco M
J Pharmacol Exp Ther; 1997 Jul; 282(1):148-61. PubMed ID: 9223550
[TBL] [Abstract][Full Text] [Related]
2. S 15535, a novel benzodioxopiperazine ligand of serotonin (5-HT)1A receptors: I. Interaction with cloned human (h)5-HT1A, dopamine hD2/hD3 and h alpha2A-adrenergic receptors in relation to modulation of cortical monoamine release and activity in models of potential antidepressant activity.
Millan MJ; Newman-Tancredi A; Rivet JM; Brocco M; Lacroix P; Audinot V; Cistarelli L; Gobert A
J Pharmacol Exp Ther; 1997 Jul; 282(1):132-47. PubMed ID: 9223549
[TBL] [Abstract][Full Text] [Related]
3. S-16924 [(R)-2-[1-[2-(2,3-dihydro-benzo[1,4]dioxin-5-yloxy)-ethyl]- pyrrolidin-3yl]-1-(4-fluorophenyl)-ethanone], a novel, potential antipsychotic with marked serotonin1A agonist properties: III. Anxiolytic actions in comparison with clozapine and haloperidol.
Millan MJ; Brocco M; Gobert A; Schreiber R; Dekeyne A
J Pharmacol Exp Ther; 1999 Mar; 288(3):1002-14. PubMed ID: 10027837
[TBL] [Abstract][Full Text] [Related]
4. The selective serotonin (5-HT)1A receptor ligand, S15535, displays anxiolytic-like effects in the social interaction and Vogel models and suppresses dialysate levels of 5-HT in the dorsal hippocampus of freely-moving rats. A comparison with other anxiolytic agents.
Dekeyne A; Brocco M; Adhumeau A; Gobert A; Millan MJ
Psychopharmacology (Berl); 2000 Sep; 152(1):55-66. PubMed ID: 11041316
[TBL] [Abstract][Full Text] [Related]
5. Selective antiaggressive effects of alnespirone in resident-intruder test are mediated via 5-hydroxytryptamine1A receptors: A comparative pharmacological study with 8-hydroxy-2-dipropylaminotetralin, ipsapirone, buspirone, eltoprazine, and WAY-100635.
de Boer SF; Lesourd M; Mocaer E; Koolhaas JM
J Pharmacol Exp Ther; 1999 Mar; 288(3):1125-33. PubMed ID: 10027850
[TBL] [Abstract][Full Text] [Related]
6. S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-Yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: I. Receptorial and neurochemical profile in comparison with clozapine and haloperidol.
Millan MJ; Gobert A; Newman-Tancredi A; Audinot V; Lejeune F; Rivet JM; Cussac D; Nicolas JP; Muller O; Lavielle G
J Pharmacol Exp Ther; 1998 Sep; 286(3):1341-55. PubMed ID: 9732398
[TBL] [Abstract][Full Text] [Related]
7. 5-HT1A and 5-HT1B receptor agonists and aggression: a pharmacological challenge of the serotonin deficiency hypothesis.
de Boer SF; Koolhaas JM
Eur J Pharmacol; 2005 Dec; 526(1-3):125-39. PubMed ID: 16310183
[TBL] [Abstract][Full Text] [Related]
8. S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: III. Actions in models of potential antidepressive and anxiolytic activity in comparison with ropinirole.
Millan MJ; Brocco M; Papp M; Serres F; La Rochelle CD; Sharp T; Peglion JL; Dekeyne A
J Pharmacol Exp Ther; 2004 Jun; 309(3):936-50. PubMed ID: 14978196
[TBL] [Abstract][Full Text] [Related]
9. The serotonin1A receptor partial agonist S15535 [4-(benzodioxan-5-yl)1-(indan-2-yl)piperazine] enhances cholinergic transmission and cognitive function in rodents: a combined neurochemical and behavioral analysis.
Millan MJ; Gobert A; Roux S; Porsolt R; Meneses A; Carli M; Di Cara B; Jaffard R; Rivet JM; Lestage P; Mocaer E; Peglion JL; Dekeyne A
J Pharmacol Exp Ther; 2004 Oct; 311(1):190-203. PubMed ID: 15146031
[TBL] [Abstract][Full Text] [Related]
10. Novel benzodioxopiperazines acting as antagonists at postsynaptic 5-HT1A receptors and as agonists at 5-HT1A autoreceptors: a comparative pharmacological characterization with proposed 5-HT1A antagonists.
Millan MJ; Canton H; Gobert A; Lejeune F; Rivet JM; Bervoets K; Brocco M; Widdowson P; Mennini T; Audinot V
J Pharmacol Exp Ther; 1994 Jan; 268(1):337-52. PubMed ID: 8301575
[TBL] [Abstract][Full Text] [Related]
11. 5-HT1A receptor agonists buspirone and gepirone attenuate apomorphine-induced aggressive behaviour in adult male Wistar rats.
Pruus K; Skrebuhhova-Malmros T; Rudissaar R; Matto V; Allikmets L
J Physiol Pharmacol; 2000 Dec; 51(4 Pt 2):833-46. PubMed ID: 11220492
[TBL] [Abstract][Full Text] [Related]
12. Anxiolytic 5-hydroxytryptamine1A agonists suppress firing activity of dorsal hippocampus CA1 pyramidal neurons through a postsynaptic mechanism: single-unit study in unanesthetized, unrestrained rats.
Tada K; Kasamo K; Ueda N; Suzuki T; Kojima T; Ishikawa K
J Pharmacol Exp Ther; 1999 Feb; 288(2):843-8. PubMed ID: 9918598
[TBL] [Abstract][Full Text] [Related]
13. F 11440, a potent, selective, high efficacy 5-HT1A receptor agonist with marked anxiolytic and antidepressant potential.
Koek W; Patoiseau JF; Assié MB; Cosi C; Kleven MS; Dupont-Passelaigue E; Carilla-Durand E; Palmier C; Valentin JP; John G; Pauwels PJ; Tarayre JP; Colpaert FC
J Pharmacol Exp Ther; 1998 Oct; 287(1):266-83. PubMed ID: 9765347
[TBL] [Abstract][Full Text] [Related]
14. Induction of burst firing in ventral tegmental area dopaminergic neurons by activation of serotonin (5-HT)1A receptors: WAY 100,635-reversible actions of the highly selective ligands, flesinoxan and S 15535.
Lejeune F; Millan MJ
Synapse; 1998 Oct; 30(2):172-80. PubMed ID: 9723787
[TBL] [Abstract][Full Text] [Related]
15. Postsynaptic 5-HT(1A) receptors mediate an increase in locomotor activity in the monoamine-depleted rat.
Mignon L; Wolf WA
Psychopharmacology (Berl); 2002 Aug; 163(1):85-94. PubMed ID: 12185404
[TBL] [Abstract][Full Text] [Related]
16. Anxiolytic activity of a novel potent serotonin 5-HT2C receptor antagonist FR260010: a comparison with diazepam and buspirone.
Harada K; Aota M; Inoue T; Matsuda R; Mihara T; Yamaji T; Ishibashi K; Matsuoka N
Eur J Pharmacol; 2006 Dec; 553(1-3):171-84. PubMed ID: 17074317
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological characterization of in vivo properties of putative mixed 5-HT1A agonist/5-HT2A/2C antagonist anxiolytics. I. Antipunishment effects in the pigeon.
Kleven MS; Koek W
J Pharmacol Exp Ther; 1996 Feb; 276(2):388-97. PubMed ID: 8632301
[TBL] [Abstract][Full Text] [Related]
18. S18616, a highly potent spiroimidazoline agonist at alpha(2)-adrenoceptors: II. Influence on monoaminergic transmission, motor function, and anxiety in comparison with dexmedetomidine and clonidine.
Millan MJ; Lejeune F; Gobert A; Brocco M; Auclair A; Bosc C; Rivet JM; Lacoste JM; Cordi A; Dekeyne A
J Pharmacol Exp Ther; 2000 Dec; 295(3):1206-22. PubMed ID: 11082458
[TBL] [Abstract][Full Text] [Related]
19. Influence of forced swimming-induced stress on the anxiolytic-like effect of 5HT(1A) agents in mice.
Briones-Aranda A; López-Rubalcava C; Picazo O
Psychopharmacology (Berl); 2002 Jul; 162(2):147-55. PubMed ID: 12110992
[TBL] [Abstract][Full Text] [Related]
20. Novel benzodioxan derivative, 5-[3-[((2S)-1,4-benzodioxan-2-ylmethyl) amino]propoxy]-1,3-benzodioxole HCl (MKC-242), with anxiolytic-like and antidepressant-like effects in animal models.
Abe M; Tabata R; Saito K; Matsuda T; Baba A; Egawa M
J Pharmacol Exp Ther; 1996 Aug; 278(2):898-905. PubMed ID: 8768745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
